Abstract
The aim of this book is to discuss both the technologies used in the discovery of melanoma biomarkers and the clinical application of these biomarkers for diagnosis and staging of disease, determination of prognosis, prediction of drug response, monitoring the efficacy of therapy, identification of novel therapeutic targets, and drug development. A broad range of biomarkers [described as any measurable molecular alteration within a cancer cell (i.e., DNA/chromosomal, mRNA, microRNA, mitochondrial DNA, epigenetic and protein)] is outlined. Of note, individual/panels or patterns of molecular markers may now be employed to stratify microscopically-similar melanocytic tumors into subsets with different biological behaviors and outcomes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gerami P, Gammon B, Murphy MJ. Melanocytic neoplasms I: molecular diagnosis. In: Murphy MJ, editor. Molecular diagnostics in dermatology and dermatopathology, Current clinical pathology and oncology. New York: Humana Press/Springer; 2011. p. 73–103.
Murphy MJ, Carlson JA. Melanocytic neoplasms II: molecular staging. In: Murphy MJ, editor. Molecular diagnostics in dermatology and dermatopathology, Current clinical pathology and oncology. New York: Humana Press/Springer; 2011. p. 105–30.
Murphy MJ, Pincelli C, Hoss DM, Borroni R. Pharmacogenetics and pharmacogenomics I: linking diagnostic classification to therapeutic decisions. In: Murphy MJ, editor. Molecular diagnostics in dermatology and dermatopathology, Current clinical pathology and oncology. New York: Humana Press/Springer; 2011. p. 419–41.
American Cancer Society. Available at http://www.cancer.org/Cancer/SkinCancer-Melanoma/DetailedGuide/melanoma-skin-cancer-key-statistics. Accessed June 26, 2011.
Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.
Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.
Chapman PB, Hauschild A, Robert C, the BRIM-3 Study Group, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med. 2011;364:2507–16.
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Murphy, M.J. (2012). Introduction to Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. In: Murphy, M. (eds) Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. Current Clinical Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-60761-433-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-60761-433-3_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-60761-432-6
Online ISBN: 978-1-60761-433-3
eBook Packages: MedicineMedicine (R0)